Antibiotics Are Man's Greatest Invention

Understanding clinical variables to improve empirical antibiotic therapy for UTI

Competing interests

F.M.W. declares personal fees and other from Bionorica, during the conduct of the study; personal fees and other from Achaogen, personal fees from AstraZeneca, personal fees and other from Bionorica, other from Enteris BioPharma, other from Helperby Therapeutics, personal fees from Janssen, personal fees from LeoPharma, personal fees from MerLion, personal fees from Merck Sharp and Dohme (MSD), personal fees and other from OM Pharma/Vifor Pharma, personal fees from Pfizer, personal fees from RosenPharma, personal fees and other from Shionogi, personal fees from VenatoRx, personal fees from GlaxoSmithKline (GSK) and other from Deutsches Zentrum für Infektionsforschung (DZIF) (Giessen-Marburg-Langen site), outside the submitted work. K.G.N declares personal fees from Adamed, personal fees from Allecra, personal fees from Apogepha, personal fees from Aristo, personal fees from Bionorica, personal fees from Biomerieux, personal fees from Enteris, personal fees from GlaxoSmithKline, personal fees from Gruenenthal Mexico, personal fees from Helperby, personal fees from Marpinion, personal fees from MerLion, personal fees from Medice, non-financial support from Mission Pharmacal, personal fees from MSD, personal fees from OM Pharma/Vifor, personal fees from Paratek, personal fees from Roche, personal fees from Saxonia and personal fees from Zambon, outside the submitted work.

Source